ALVAL — Valbiotis SA Share News
0.000.00%
Last trade - 00:00- €18.60m
- €11.17m
- €0.91m
Brief: Valbiotis Signs Exclusive Agreement With ADECAL-Technopole And IFREMER
Brief: Valbiotis Announces Completion Of Recruitment For Phase II HEART Clinical Study Conducted With TOTUM•070
Brief: Valbiotis: Implementation Of Totum 63 At Laval University In Quebec City
Brief: Valbiotis Announces Publication Of First Scientific Papers On TOTUM•63
Brief: Valbiotis Granted Eur 1.25 Mln Innovation Support Loan By Bpifrance
Brief: Valbiotis Obtains Patent For Active Substance Totum-63 In China
Brief: Valbiotis Completes Capital Increase Of 15 Million Euros
Brief: Valbiotis Launches Cash Capital Increase Of Around 12 Million Euros
Brief: Valbiotis FY Operating Loss Narrows To EUR 3.4 Mln
Brief: Valbiotis' TOTUM-854 To Enter Clinical Development Phase In 2021
Brief: Valbiotis Announces First Patient's Visit In Phase II HEART Clinical Study
Valbiotis: Rises as cholesterol drug phase II study green-lighted
Brief: Valbiotis Authorised For Phase 2 HEART Study In Reducing Cholesterol
Brief: Valbiotis Presents First Market Data On Untreated LDL-Hypercholesterolemia For Totum-070
Brief: Valbiotis Joins EnterNext PEA-PME 150 Index From Euronext Paris
Brief: Valbiotis H1 Revenue Up At 121,000 Euros
Brief: Valbiotis Receives US And European TOTUM-070 Patent For Reducing Hypercholesterolemia
Brief: Valbiotis Announces Cash Position Of 10.9 Million Euros At 30 June
Brief: Valbiotis Announces Capital Increase via EUR 2 Mln Private Placement